Based on the findings of this study, we developed a laboratory Bcl-2 inhibitor workflow for identifying IDH1/2 and DNMT3A mutations in the first diagnosis and relapse without using of sequencing (Figure 9).

HRM analysis should be the method of choice for differentiating between wt and all the analysed mutations in primary AML samples. In case of uncertainty results can be verified Lorlatinib clinical trial using the above presented methods. In addition, ARMS and endonuclease restriction provide a possibility to identify the most common IDH2 and DNMT3A mutations when no HRM-compatible real-time PCR cycler is available. Because of the multiplicity of IDH1 mutations, it was not possible to generate a valid method for analysing 1 specific mutation. For this reason HRM analysis is the best alternative to Sanger sequencing. After

therapy, follow-up analysis should be chosen depending on the identified mutations at the first diagnosis. Because endonuclease restriction had higher sensitivity for R882H mutations, this method is more suitable for detecting low mutational ratio of known mutations in patients after therapy or relapse and progression of disease. Because learn more of the ease of interpretation ARMS can also be used to identify IDH2 R140Q mutations at relapse or disease progression. Table 1 Comparative characteristics of all the methods used in this study   DNMT3A IDH2 IDH1   Restriction endonuclease HRM Sanger sequencing ARMS HRM Sanger sequencing HRM Sanger sequencing Sensitivity*, % 0.05 5.9 10 4.5 4.5

10 6 to 7.8 10 Turnaround time, days 1 1 2 to 3 1 1 2 to 3 1 2 to 3 Technician time, hours 4 3.5 10 to 12 3 3.5 10 to 12 3.5 10 to 12 Cost of diagnosis method, € 32.13 28 122 44.16 28 122 28 122 Interpretation Easy Medium -difficult Medium Easy Medium -difficult Medium Medium -difficult Medium Identification of different/rare mutations No Yes Yes No Yes Yes Yes Yes Special equipment PCR cycler HRM real time PCR cycler Sequencer PCR cycler HRM real time real time PCR cycler Sequencer HRM real time real time PCR cycler Oxymatrine Sequencer *Sensitivity was measured as the minimal percentage of mutated allele in a sample detected by the assay. Figure 9 Possible diagnostic workflow to identify DNMT3A, IDH2 and IDH1 mutations in routine laboratory analysis. HRM analysis can be performed in the first diagnosis for all mutations because of high mutational ratios prior to therapy. Unclear results can be verified by endonuclease restriction or ARMS-PCR. Unclear IDH1 results can be checked by sequencing because of the heterogeneity of possible mutations. Effective combination of all the available methods enables more reliable results and a cost-effective and time-saving routine laboratory analysis.